VaishaliMankadMD
Allergy & Immunology • Durham, NCGlobal Development Medical Director, Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca
Dr. Mankad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4309 Emperor Boulevard
Suite 400
Durham, NC 27703
Education & Training
Duke University HospitalFellowship, Allergy and Immunology, 2003 - 2005- Duke University HospitalResidency, Pediatrics, 1998 - 2001
University of Illinois College of MedicineClass of 1998
Certifications & Licensure
NC State Medical License 2001 - 2025
VA State Medical License 2007 - 2010- American Board of Allergy and Immunology Allergy & Immunology
Awards, Honors, & Recognition
- AoA AoA
Publications & Presentations
PubMed
- 69 citationsNirsevimab for Prevention of RSV in Term and Late-Preterm Infants.William J Muller, Shabir A Madhi, Beatriz Seoane Nuñez, Manuel Baca Cots, Miroslava Bosheva
The New England Journal of Medicine. 2023-04-20 - 338 citationsNirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.Laura L Hammitt, Ron Dagan, Yuan Yuan, Manuel Baca Cots, Miroslava Bosheva
The New England Journal of Medicine. 2022-03-03 - 65 citationsSafety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.Joseph Domachowske, Shabir A Madhi, Eric A F Simões, Victoria Atanasova, Fernando Cabañas
The New England Journal of Medicine. 2022-03-03
Professional Memberships
- Member
Industry Relationships
- Global Development Medical Director, AstraZenecaLate phase clinical developmentDisclosure: Employee2020 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
